Genvor Incorporated
OOTC:GNVR0.75
USD
+0.14
(+21.95%)
CIK
1792941
ISIN
US37254K1007
CUSIP
37254K100
Return %
Stock
S&P 500
1Y
-50.00
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Chad Pawlak
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Henderson United States
- IPO Date
- Sep 1, 2023
- CIK
- 0001792941
- Website
- genvor.com
- Similar Companies
- Business
- Genvor Incorporated operates as an agricultural biotechnology and life sciences company focused on the discovery, design, and commercialization of artificial intelligence-engineered peptide solutions for sustainable crop protection, plant enhancement, and human health and wellness. The company leverages its proprietary BioCypher platform, a computational biology and machine learning engine supported by a proprietary library of over 50,000 designed peptides, to develop biological molecules that are deployed through seed trait integration and foliar spray formulations. Genvor Incorporated develops and offers antimicrobial peptides (AMPs) engineered to control bacterial and fungal pathogens, including lead candidate AGM182 co-developed with the U.S. Department of Agriculture to suppress Aspergillus flavus and reduce aflatoxin contamination in corn; nutrient-enhancing peptides (NEPs) designed to improve nutrient assimilation, root health, and plant vigor; insecticidal peptides for targeted biological pest management; crop-enhancement peptides (CEPs) focused on increasing crop yields and abiotic stress tolerance; and human wellness bioactive peptides formulated for weight management, cellular recovery, tissue repair, anti-aging, and hormonal balance. The company operates under a licensing-first business model, targeting agricultural seed companies, agrochemical manufacturers, crop growers, and consumer healthcare markets primarily within the United States. Founded in 2018 and formerly known as Allure Worldwide, Inc. prior to its corporate restructuring and rebranding in June 2022, Genvor Incorporated is headquartered in Henderson, Nevada, with wet-lab research and development facilities located in Woodland, California. In recent developments, the company broadened its operational focus into human health by executing a strategic Memorandum of Understanding with Canlab International to co-develop and commercialize a pipeline of natural bioactive peptide candidates; expanded its agricultural research partnerships with the USDA Agricultural Research Service to evaluate antimicrobial peptides for pathogen control in sugar beet production and storage; and appointed Donald Kalkofen as Chief Financial Officer to oversee its financial strategy, capital restructuring initiatives, and dual-market commercial growth on the OTCQB Venture Market under the ticker GNVR.